NAFLD and NASH: etiology, targets and emerging therapies

Shulin Wei; Li Wang; Paul C. Evans; Suowen Xu

doi:10.1016/j.drudis.2024.103910

NAFLD and NASH: etiology, targets and emerging therapies

Shulin Wei
, Li Wang
, Paul C. Evans
, Suowen Xu^*

^*Corresponding author for this work

Department of Biomedical Sciences

Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review

167 Citations (Scopus)

Abstract

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) pose a significant threat to human health and cause a tremendous socioeconomic burden. Currently, the molecular mechanisms of NAFLD and NASH remain incompletely understood, and no effective pharmacotherapies have been approved. In the past five years, significant advances have been achieved in our understanding of the pathomechanisms and potential pharmacotherapies of NAFLD and NASH. Research advances include the investigation of the effects of the fibroblast growth factor 21 (FGF21) analog pegozafermin and the thyroid hormone receptor-β (THRβ) agonist resmetriom on hepatic fat content, NASH resolution and/or fibrosis regression. Future directions of NAFLD and NASH research (including combination therapy, organoids and humanized mouse models) are also discussed in this state-of-the-art review. © 2024 Elsevier Ltd

Original language	English
Article number	103910
Number of pages	14
Journal	Drug Discovery Today
Volume	29
Issue number	3
Online published	1 Feb 2024
DOIs	https://doi.org/10.1016/j.drudis.2024.103910
Publication status	Published - 14 Feb 2024

Funding

This study was supported by grants from the National Key R&D Program of China (Grant No. 2021YFC2500500), the National Natural Science Foundation of China (Grant Nos. 82370444 and 82070464) and the Strategic Priority Research Program of the Chinese Academy of Sciences (Grant No. XDB38010100). This work was also supported by the Program for Innovative Research Team of The First Affiliated Hospital of USTC (CXGG02), Anhui Provincial Key Research and Development Program (Grant No. 202104j07020051) and Anhui Provincial Natural Science Foundation (Grant No. 2208085J08). S.X. is a recipient of a Humboldt fellowship from the Alexander von Humboldt Foundation, Germany.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access Output

10.1016/j.drudis.2024.103910

Other Access Options

Check CityUHK Library

Permanent Link

Right click to copy link

Cite this

@article{5da52c3f13cd477aa79a31974dc5b2a6,

title = "NAFLD and NASH: etiology, targets and emerging therapies",

abstract = "Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) pose a significant threat to human health and cause a tremendous socioeconomic burden. Currently, the molecular mechanisms of NAFLD and NASH remain incompletely understood, and no effective pharmacotherapies have been approved. In the past five years, significant advances have been achieved in our understanding of the pathomechanisms and potential pharmacotherapies of NAFLD and NASH. Research advances include the investigation of the effects of the fibroblast growth factor 21 (FGF21) analog pegozafermin and the thyroid hormone receptor-β (THRβ) agonist resmetriom on hepatic fat content, NASH resolution and/or fibrosis regression. Future directions of NAFLD and NASH research (including combination therapy, organoids and humanized mouse models) are also discussed in this state-of-the-art review. {\textcopyright} 2024 Elsevier Ltd",

author = "Shulin Wei and Li Wang and Evans, \{Paul C.\} and Suowen Xu",

year = "2024",

month = feb,

day = "14",

doi = "10.1016/j.drudis.2024.103910",

language = "English",

volume = "29",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier Ltd.",

number = "3",

}

TY - JOUR

T1 - NAFLD and NASH

T2 - etiology, targets and emerging therapies

AU - Wei, Shulin

AU - Wang, Li

AU - Evans, Paul C.

AU - Xu, Suowen

PY - 2024/2/14

Y1 - 2024/2/14

N2 - Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) pose a significant threat to human health and cause a tremendous socioeconomic burden. Currently, the molecular mechanisms of NAFLD and NASH remain incompletely understood, and no effective pharmacotherapies have been approved. In the past five years, significant advances have been achieved in our understanding of the pathomechanisms and potential pharmacotherapies of NAFLD and NASH. Research advances include the investigation of the effects of the fibroblast growth factor 21 (FGF21) analog pegozafermin and the thyroid hormone receptor-β (THRβ) agonist resmetriom on hepatic fat content, NASH resolution and/or fibrosis regression. Future directions of NAFLD and NASH research (including combination therapy, organoids and humanized mouse models) are also discussed in this state-of-the-art review. © 2024 Elsevier Ltd

AB - Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) pose a significant threat to human health and cause a tremendous socioeconomic burden. Currently, the molecular mechanisms of NAFLD and NASH remain incompletely understood, and no effective pharmacotherapies have been approved. In the past five years, significant advances have been achieved in our understanding of the pathomechanisms and potential pharmacotherapies of NAFLD and NASH. Research advances include the investigation of the effects of the fibroblast growth factor 21 (FGF21) analog pegozafermin and the thyroid hormone receptor-β (THRβ) agonist resmetriom on hepatic fat content, NASH resolution and/or fibrosis regression. Future directions of NAFLD and NASH research (including combination therapy, organoids and humanized mouse models) are also discussed in this state-of-the-art review. © 2024 Elsevier Ltd

UR - https://www.scopus.com/pages/publications/85185708441

UR - https://www.scopus.com/record/pubmetrics.uri?eid=2-s2.0-85185708441&origin=recordpage

U2 - 10.1016/j.drudis.2024.103910

DO - 10.1016/j.drudis.2024.103910

M3 - RGC 21 - Publication in refereed journal

C2 - 38301798

SN - 1359-6446

VL - 29

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 3

M1 - 103910

ER -

NAFLD and NASH: etiology, targets and emerging therapies

Abstract

Funding

UN SDGs

Access Output

Other Access Options

Permanent Link

Other Files and Links

Fingerprint

Cite this